Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a stock price increase of over 6%, currently trading at 13.41 HKD with a transaction volume of 20.88 million HKD, following the announcement of a new clinical trial for its drug TYK-01054 [1] Group 1: Clinical Trial Information - A clinical trial for the TEAD inhibitor TYK-01054 capsule has been initiated, focusing on safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with locally advanced or metastatic solid tumors [1] - The trial is an I/II phase, open-label, multi-center study, with the registration number CTR20255003, and the first public information date is December 26, 2025 [1] Group 2: Drug and Indication - TYK-01054 capsule is a chemical drug indicated for advanced solid tumors, which refers to cancer cells that have spread to other parts of the body [1] - Symptoms of advanced solid tumors vary by tumor type and commonly include pain and fatigue, with diagnosis relying on imaging studies and pathological biopsies [1]
同源康医药-B现涨超6% TYK-01054胶囊启动I/II期临床 适应症为晚期实体瘤